LLY
Eli Lilly and Company
LLY has the edge over STXS overall, supported by stronger fundamentals and lower modeled downside.
STXS
Stereotaxis, Inc.
STXS's outlook is improving, though it still trails on the overall score.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
STXS Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Weak | |
| Unavailable |
STXS's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
STXS PE Valuation
STXS has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
STXS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect STXS's losses to shrink, with revenue growing.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over STXS on earnings quality, reporting a profit while its opponent remains loss making.
STXS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.24 | +$0.05 |
| Q1 2026 | -$0.24 | +$0.07 |
| Q4 2025 | -$0.25 | +$0.05 |
| Q3 2025 | -$0.28 | -$0.01 |
| Q2 2025 | -$0.29 | -$0.03 |
| Q1 2025 | -$0.31 | -$0.05 |
| Q4 2024 | -$0.30 | -$0.03 |
| Q3 2024 | -$0.27 | $0.00 |
STXS is still losing money, but less than at its worst: $0.24 per share over the past year, against $0.31 at its worst in early 2025.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over STXS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over STXS on profitability, with a higher operating margin.
STXS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $7.7M | -13% |
| Q1 2026 | $6.3M | -16% |
| Q4 2025 | $8.6M | +36% |
| Q3 2025 | $7.5M | -19% |
| Q2 2025 | $8.8M | +95% |
| Q1 2025 | $7.5M | +8.6% |
| Q4 2024 | $6.3M | +39% |
| Q3 2024 | $9.2M | +18% |
STXS's revenue has slid since its 2024 peak: $8M last quarter, down 13% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -60% | -14 points |
| Q1 2026 | -95% | -16 points |
| Q4 2025 | -65% | +55 points |
| Q3 2025 | -88% | -19 points |
| Q2 2025 | -45% | +89 points |
| Q1 2025 | -79% | -10 points |
| Q4 2024 | -120% | -4.1 points |
| Q3 2024 | -69% | +3.3 points |
STXS's operating margin was −60% last quarter, down 14 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with STXS at down 101%.
STXS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$3.5M | -$1.7M |
| Q4 2025 | -$4M | -420% |
| Q3 2025 | -$4.2M | +$135K |
| Q4 2024 | $1.3M | +$3.7M |
| Q3 2024 | -$4.3M | -$3.4M |
| Q4 2023 | -$2.4M | +$482K |
| Q3 2023 | -$977K | +$1.8M |
| Q2 2023 | -$2.9M | -$1.2M |
STXS has burned cash in almost every quarter: −$16M over the past year, against −$7M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over STXS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
STXS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +1.1M shares |
| 1 year | +14% | +12.1M shares |
| 3 years | +23% | +19M shares |
| 5 years | +32% | +24.5M shares |
| Available history | +56% | +35.7M shares |
STXS has 100M diluted shares, up 14% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
STXS Net Leverage
STXS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
STXS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 31.1 | Neutral |
| Stochastic | 18.5 | Oversold |
STXS's weekly RSI is 31 (neutral) and its Stochastic is 18 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
STXS PE vs Healthcare Sector
STXS has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over STXS on trend strength, trading above more of its moving averages.
STXS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.05 | 19% below |
| 20 week MA | $1.28 | 34% below |
| 50 week MA | $1.76 | 52% below |
| 100 week MA | $2.05 | 59% below |
| 200 week MA | $2.02 | 58% below |
STXS is in a downtrend: it's below all five of its weekly moving averages, and 58% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over STXS on returns for 2026, with the stronger performance.
STXS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.03 | $5.14 | +2.2% |
| 2021 | $5.14 | $6.26 | +22% |
| 2022 | $6.26 | $2.03 | -68% |
| 2023 | $2.03 | $1.75 | -14% |
| 2024 | $1.75 | $2.29 | +31% |
| 2025 | $2.29 | $2.46 | +7.4% |
| 2026 YTD | $2.46 | $0.85 | -65% |
STXS is down 65% so far in 2026, after finishing higher in four of the previous six years.